Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size

Abstract

Background. There is no consensus on a universal dosing method for calculating high-dose chemotherapy in allogeneic Stem Cell Transplant (SCT) patients. The Metropolitan Life (Met-Life) Insurance Company’s weight—height tables have been used to determine body weight for chemotherapy dosing for SCT, however no formal study has been done to determine if the Met-Life weight— height tables can be used for chemotherapy dosing in SCT. We retrospectively studied the use of Met-Life weight—height tables for chemotherapy dosing in SCT. Our goal is to determine if patients with extremes of body size who had undergone an SCT and were dosed according to the Met-Life weight— height tables had an increase of Treatment Related Morbidity (TRM) or mortality or relapse.

Patients and Methods. Patients were grouped into three different treatment regimens, cyclophosphamide/TBI, busulphan/cyclophosphamide, and AraC/cyclophosphamide/TBI. Patients in each treatment regimen were further divided into five equal groups based on weight. Treatment related morbidity and mortality was evaluated by comparing the lowest and highest quintiles to the middle quintiles within each treatment regimen.

Result. Data from 262 patients was evaluated in this study. Overall, there was not an increase in TRM or mortality or in relapse in patients with extremes of body size.

Conclusion. The Met-Life weight—height tables could be used to dose patients undergoing allogeneic SCTs. Additional prospective studies would need to be done comparing other chemotherapy dosing methods with the Met-Life weight—height tables to further validate this conclusion.

Keywords

allogeneic stem cell transplant drug dosing body surface area

Get full access to this article

View all access options for this article.

References

Meloni G. , Proia A. , Capria S. , Romano A. , Trape G. , Trisolini SM et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 2001; 28: 365-7.

Grigg A. , Harrun MH , Szer J. Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey . Leuk Lymphoma 1997; 25: 487-91.

Health implications of obesity.. National Institutes of Health Consensus Development Conference Statement . Ann of Intern Med 1985; 103(6(Pt 2): 1073-7.

Pai MP , Paloucek FP The origin of ‘‘ideal’’ body weight equations . Ann Pharmacother 2000; 34: 1066-9.

Himes JH , Bouchard C.

Do the new metropolitan life insurance weight-height tables correctly assess body frame and body fat relationships?

Am J Public Health 1985; 75: 1076-9.

Metropolitan Life Insurance Company.. 1983 Metropolitan height and weight tables. Stat Bull 1983; 64: 3-9.

Ogden CL , Carroll MD , Curtin LR , McDowell MA , Tabak CJ , Flegal KM Prevalence of Overweight and Obesity in the United States, 1999-2004 . JAMA 2006; 295: 1549-55.

Navarro WH Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003; 31: 961-6.

Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. (http://ctep.cancer.gov ).

10.

Dickson TMC , Kusnierz-Glaz CR , Blume KG , Negrin RS , Hu WW , Shizuru JA et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation . Biol Blood Marrow Transplant 1999; 5: 299-305.

11.

Fleming DR , Rayens MK , Barrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 1997; 102: 265-8.

12.

Nieto Y. , Vaughan WP Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259-69.

13.

Braess J. , Pförtner J. , Kern W. , Hiddemann W. , Schleyer E. Cytidine Deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 1999 ; 78: 514-20.

14.

Braess J. , Wegendt C. , Feuring-Buske M. , Riggert J. , Kern W. , Hiddemann W. et al. Leukemic blasts differ from normal bone marrow mononuclear cells and CD34+ haematopoetic stem cells in their metabolism of cytosine arabinoside . Br J Haematol 1999; 105: 388-93.

15.

Green B. , Duffull SB

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Br J ClinPharmacol 2004; 58: 119-33.

16.

Singhal S. Gordon L. , Tallman M. , Winter J. , Williams S. , Frankfurt O. et al. Submyeloablative allogeneic HSCT for hematologic malignancies: effect of body weight blood. 2005 abst. 2949.